Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Evotec AG
Specializes in the discovery and development of new drugs

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.

It operates through the EVT Execute and EVT Innovate segments.

The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include research fees, milestones and royalties.

The EVT Innovate segment focuses on building a longterm partnered pharmaceutical pipeline from its own, internally developed assets and platforms.

The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Number of employees : 1 238 persons.
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
Europe72.7857%97.0659% +33.37%
United States53.6242%65.8040% +22.71%
Japan and Rest of the World1.281%1.651% +28.85%
Managers
NameAgeSinceTitle
Werner Lanthaler, PhD502009Chief Executive Officer
Wolfgang Plischke, PhD672014Chairman-Supervisory Board
Mario Polywka, PhD552004Chief Operating Officer
Enno Spillner, MBA482016Chief Financial Officer
Cord E. Dohrmann, PhD542010Chief Scientific Officer
Claus Tycho Bræstrup, MD732013Independent Member-Supervisory Board
Bernd Hirsch482013Vice Chairman-Supervisory Board
Iris Löw-Friedrich MD, PhD582014Independent Member-Supervisory Board
Elaine Sullivan, PhD572015Member-Supervisory Board
Michael Shalmi MD, MBA532017Member-Supervisory Board
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 147,532,681 133,882,766 90.7% 249,915 0.2% 90.7%
Shareholders
NameEquities%
Novo Nordisk Fonden 14,767,926 10.0%
Roland Oetker 13,400,000 9.09%
Allianz Global Investors GmbH 7,396,020 5.01%
Deutsche Asset Management Investment GmbH 5,315,392 3.60%
JPMorgan Asset Management (UK) Ltd. 4,869,421 3.30%
The Vanguard Group, Inc. 3,028,290 2.05%
Norges Bank Investment Management 2,371,757 1.61%
Principal Global Investors LLC 1,668,432 1.13%
Goldman Sachs Asset Management LP 1,545,666 1.05%
BlackRock Asset Management Deutschland AG 1,447,324 0.98%
Holdings
NameEquities%Valuation
Evotec AG (EVT) 249,9150.17%3,674,170 USD
Company contact information
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
Hamburg 22419

Phone : +49.40.56081.0
Fax : +49.40.56081.222
Web : www.evotec.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG6.04%2 592
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.42%20 432
INCYTE CORPORATION-0.68%19 852
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692
NEKTAR THERAPEUTICS20.56%11 338
ALKERMES PLC7.27%9 028
SYNEOS HEALTH INC-6.08%8 546
QIAGEN0.00%7 537
SEATTLE GENETICS, INC.-2.13%7 536
SAGE THERAPEUTICS INC6.77%7 220
IONIS PHARMACEUTICALS INC5.81%6 618
EXACT SCIENCES CORPORATION0.15%6 300
ICON PLC1.00%6 121
UNITED THERAPEUTICS CORPORATION-4.52%6 104
GALAPAGOS16.81%5 768
PRA HEALTH SCIENCES INC-1.11%5 707
BIO-TECHNE CORP8.08%5 245
CHARLES RIVER LABORATORIES INTL. INC-3.76%4 989
FIBROGEN INC4.43%4 069
Connections : Evotec AG
German Chemical Industry Fund
European Chemical Industry Council
Bundesverband der Deutschen Industrie e.V.
IOLTECH SA
Walter Siegenthaler Gesellschaft
Momentum Gruppen A/S
Robert Koch Stiftung eV
Technology Academy Finland
Forge Therapeutics, Inc.
Bayer Technology Services GmbH
Evotect (India) Pvt Ltd.
Bayer Real Estate GmbH
Bertelsmann, Inc.
Bayer Innovation GmbH
German Asia Pacific Business Association
Bankinvest Biomedical Venture
University of Hohenheim
The Royal Danish Scientific Society
Helmholtz-Gemeinschaft Deutscher Forschungszentren eV
Paul Ehrlich-Foundation
Novo Principal Investments
Penguin Random House LLC
Concentro Management AG
Penguin Random House Ltd.
Johann Wolfgang Goethe-Universität Frankfurt am Main
Hoechst Marion Roussel, Inc.
Eternygen GmbH
Carrick Therapeutics Ltd.
IP Group Plc /Venture Capital/
Aerocrine AB
Topas Therapeutics GmbH
Ataxion, Inc.
Synlab International GmbH
© 2018 People , Fundamentals and Ownership